Cynthia Retna Sartika
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cynthia Retna Sartika has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Karina Kalasuba
PT. Prodia Stemcell Indonesia
3 shared publications Rima Haifa
PT. Prodia Stemcell Indonesia
2 shared publications- Rima Haifa
PT Prodia StemCell Indonesia, Jl. Kramat VII No.11-13, Jakarta 10430
2 shared publications - Ahmad Faried
Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
1 shared publication Andi Wijaya
Prodia Clinical Laboratory, Jl. Kramat Raya No. 150, Jakarta 10430
1 shared publicationAngliana Chouw
PT. Prodia Stemcell Indonesia
1 shared publication
Latest Publications
- Open Access
- 14 November 2026
- Published by Secretariat of The Indonesian Biomedical Journal in The Indonesian Biomedical Journal
- Vol. 18 (5) , 461-8
Intraparenchymal Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Subacute Ischemic Stroke: A Preliminary Study of Safety and Early Clinical Outcomes
BACKGROUND: Intravenous thrombolysis and mechanical thrombectomy are current standard treatments for ischemic stroke, however their narrow therapeutic window limits eligibility for many patients. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have emerged as a promising regenerative therapy, but their safety and efficacy need to be further elucidated. Interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) may provide biological insights into the inflammatory and neuroregenerative responses following UC-MSC transplantation. This study was conducted to evaluate the safety and preliminary efficacy, including IL-6 and BDNF level, after stereotactic intraparenchymal UC-MSC transplantation.METHODS: Subjects with subacute ischemic stroke received stereotactic intraparenchymal transplantation of 2×10⁷ allogeneic UC-MSCs into the perolesional ischemic area, 13 to 20 days after stroke onset. Safety was assessed by monitoring the adverse events. Early efficacy was evaluated using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Magnetic Resonance Imaging (MRI), and serum biomarkers, including IL-6 and BDNF. Serum IL-6 levels were measured using electrochemiluminescence immunoassay (ECLIA), while BDNF levels were measured using enzyme-linked immunosorbent assay (ELISA).RESULTS: No serious adverse events related to UC-MSCs administration were observed during the three-month follow-up. No serious adverse events related to UC-MSC administration were observed during the three-month follow-up. From baseline to the third month, improved mRS and NIHSS scores were observed (mean Δ: −0.75 and +4.00, respectively), along with reduced IL-6 (mean Δ: −2.76 pg/mL) and increased BDNF (mean Δ: +3.16 ng/mL).CONCLUSION: UC-MSC transplantation was well tolerated, with improvements in NIHSS and mRS and favorable changes in IL-6 and BDNF levels. These findings suggest that direct intraparenchymal UC-MSCs transplantation may be safe, as no severe adverse events were observed in this preliminary study.KEYWORDS: ischemic stroke, umbilical cord-derived mesenchymal stem cells (UC-MSCs), interleukin-6, brain-derived neurotrophic factor
- 14 November 2026
- Published by Secretariat of The Indonesian Biomedical Journal in The Indonesian Biomedical Journal
- Vol. 18 (5) , 461-8
Open AccessIntraparenchymal Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Subacute Ischemic Stroke: A Preliminary Study of Safety and Early Clinical Outcomes
BACKGROUND: Intravenous thrombolysis and mechanical thrombectomy are current standard treatments for ischemic stroke, however their narrow therapeutic window limits eligibility for many patients. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have emerged as a promising regenerative therapy, but their safety and efficacy need to be further elucidated. Interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) may provide biological insights into the inflammatory and neuroregenerative responses following UC-MSC transplantation. This study was conducted to evaluate the safety and preliminary efficacy, including IL-6 and BDNF level, after stereotactic intraparenchymal UC-MSC transplantation.METHODS: Subjects with subacute ischemic stroke received stereotactic intraparenchymal transplantation of 2×10⁷ allogeneic UC-MSCs into the perolesional ischemic area, 13 to 20 days after stroke onset. Safety was assessed by monitoring the adverse events. Early efficacy was evaluated using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Magnetic Resonance Imaging (MRI), and serum biomarkers, including IL-6 and BDNF. Serum IL-6 levels were measured using electrochemiluminescence immunoassay (ECLIA), while BDNF levels were measured using enzyme-linked immunosorbent assay (ELISA).RESULTS: No serious adverse events related to UC-MSCs administration were observed during the three-month follow-up. No serious adverse events related to UC-MSC administration were observed during the three-month follow-up. From baseline to the third month, improved mRS and NIHSS scores were observed (mean Δ: −0.75 and +4.00, respectively), along with reduced IL-6 (mean Δ: −2.76 pg/mL) and increased BDNF (mean Δ: +3.16 ng/mL).CONCLUSION: UC-MSC transplantation was well tolerated, with improvements in NIHSS and mRS and favorable changes in IL-6 and BDNF levels. These findings suggest that direct intraparenchymal UC-MSCs transplantation may be safe, as no severe adverse events were observed in this preliminary study.KEYWORDS: ischemic stroke, umbilical cord-derived mesenchymal stem cells (UC-MSCs), interleukin-6, brain-derived neurotrophic factor
- Open Access
- 12 June 2026
- Published by SAGE Publications in Cell Transplantation
- Vol. 35
Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy
Mesenchymal stromal cell (MSC)–based therapies have demonstrated broad therapeutic potential across inflammatory, degenerative, and neurological disorders; however, clinical outcomes remain highly variable, largely due to heterogeneity in cell source, dosing strategies, routes of administration, treatment timing, and patient-specific factors. This review evaluates how MSC dose and delivery route influence clinical efficacy and safety, and whether specific administration routes require tailored dosing strategies. A systematic literature search of PubMed, Scopus, Web of Science, and the Cochrane Library (2015–2025) identified 29 eligible clinical trials employing intravenous (n = 13), intrathecal (n = 10), intramuscular (n = 4), intranasal (n = 1), and multi-route (n = 1) administration, with doses ranging from 2 × 10 5 cells/kg body weight to fixed doses exceeding 1 × 10 8 cells. Intravenous delivery was predominantly used for systemic indications but was limited by pulmonary first-pass sequestration, whereas intrathecal and intranasal routes enhanced central nervous system targeting and intramuscular administration supported prolonged local persistence and paracrine activity. Although MSC therapy was generally well tolerated across studies, substantial outcome variability underscores the need for harmonized frameworks for dose selection, route optimization, and manufacturing consistency. This review highlights critical gaps in dose–route optimization and supports the development of standardized clinical guidelines and advanced strategies, including MSC priming and engineering, to improve therapeutic predictability and translational success.
- 12 June 2026
- Published by SAGE Publications in Cell Transplantation
- Vol. 35
Open AccessOptimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy
Mesenchymal stromal cell (MSC)–based therapies have demonstrated broad therapeutic potential across inflammatory, degenerative, and neurological disorders; however, clinical outcomes remain highly variable, largely due to heterogeneity in cell source, dosing strategies, routes of administration, treatment timing, and patient-specific factors. This review evaluates how MSC dose and delivery route influence clinical efficacy and safety, and whether specific administration routes require tailored dosing strategies. A systematic literature search of PubMed, Scopus, Web of Science, and the Cochrane Library (2015–2025) identified 29 eligible clinical trials employing intravenous (n = 13), intrathecal (n = 10), intramuscular (n = 4), intranasal (n = 1), and multi-route (n = 1) administration, with doses ranging from 2 × 10 5 cells/kg body weight to fixed doses exceeding 1 × 10 8 cells. Intravenous delivery was predominantly used for systemic indications but was limited by pulmonary first-pass sequestration, whereas intrathecal and intranasal routes enhanced central nervous system targeting and intramuscular administration supported prolonged local persistence and paracrine activity. Although MSC therapy was generally well tolerated across studies, substantial outcome variability underscores the need for harmonized frameworks for dose selection, route optimization, and manufacturing consistency. This review highlights critical gaps in dose–route optimization and supports the development of standardized clinical guidelines and advanced strategies, including MSC priming and engineering, to improve therapeutic predictability and translational success.
- Open Access
- 13 March 2026
- Published by Open Medical Publishing in Orthopedic Reviews
- Vol. 18, 158292
Influence of Synovial Fluid Biochemical Markers on Clinical Outcomes Following Arthroscopic and Non-Arthroscopic Patients with Knee Osteoarthritis
Background: Osteoarthritis (OA) is a degenerative joint disorder that causes pain, stiffness, and functional impairment. Conventional treatments relieve symptoms but do not restore cartilage, limiting long-term efficacy. Cell-based therapies, including mesenchymal stem cells (MSCs) and MSC-derived secretome, have emerged as promising strategies for cartilage regeneration. Object: This study aimed to assess the therapeutic effects of UC-MSCs and UC-MSC-derived secretome in OA patients through both clinical outcomes and synovial fluid (SF) analyses. Methods: Eligible participants were divided into two groups; group who underwent arthroscopy and group who did not. All the participants received an intra-articular injection consisting of an initial 2 mL dose of UC-MSC secretome, followed by 10 million UC-MSCs, and two additional 2 mL doses of secretome administered biweekly. Synovial fluid samples were collected at baseline and 12 weeks post-treatment, centrifuged to obtain the supernatant, and analyzed for inflammatory cytokines and matrix-degrading markers using multiplex and ELISA assays. Clinical evaluations were conducted at 6- and 12-months post-treatment. Result: The results showed that UC-MSC therapy significantly improved functional outcomes in patients with knee osteoarthritis, as indicated by WOMAC scores up to six months. In vitro studies showed similar results, where co-culture of osteoarthritic synovial fluid-derived MSCs with UC-MSCs or UC-MSC secretome enhanced proliferation and differentiation while rapidly reducing pro-inflammatory cytokines (IL-1β, IFN-γ, IL-6, IL-12p70, IL-17A, IL-18) and MMPs (MMP1, MMP7, MMP13). Conclusion: Our findings support a two-stage therapeutic strategy in which UC-MSC secretome first alleviates inflammation, followed by UC-MSCs to promote cartilage regeneration. Post-injection rehabilitation or repeated MSC dosing may further enhance treatment efficacy, highlighting the potential of MSC-based therapies for knee OA management.
- 13 March 2026
- Published by Open Medical Publishing in Orthopedic Reviews
- Vol. 18, 158292
Open AccessInfluence of Synovial Fluid Biochemical Markers on Clinical Outcomes Following Arthroscopic and Non-Arthroscopic Patients with Knee Osteoarthritis
Background: Osteoarthritis (OA) is a degenerative joint disorder that causes pain, stiffness, and functional impairment. Conventional treatments relieve symptoms but do not restore cartilage, limiting long-term efficacy. Cell-based therapies, including mesenchymal stem cells (MSCs) and MSC-derived secretome, have emerged as promising strategies for cartilage regeneration. Object: This study aimed to assess the therapeutic effects of UC-MSCs and UC-MSC-derived secretome in OA patients through both clinical outcomes and synovial fluid (SF) analyses. Methods: Eligible participants were divided into two groups; group who underwent arthroscopy and group who did not. All the participants received an intra-articular injection consisting of an initial 2 mL dose of UC-MSC secretome, followed by 10 million UC-MSCs, and two additional 2 mL doses of secretome administered biweekly. Synovial fluid samples were collected at baseline and 12 weeks post-treatment, centrifuged to obtain the supernatant, and analyzed for inflammatory cytokines and matrix-degrading markers using multiplex and ELISA assays. Clinical evaluations were conducted at 6- and 12-months post-treatment. Result: The results showed that UC-MSC therapy significantly improved functional outcomes in patients with knee osteoarthritis, as indicated by WOMAC scores up to six months. In vitro studies showed similar results, where co-culture of osteoarthritic synovial fluid-derived MSCs with UC-MSCs or UC-MSC secretome enhanced proliferation and differentiation while rapidly reducing pro-inflammatory cytokines (IL-1β, IFN-γ, IL-6, IL-12p70, IL-17A, IL-18) and MMPs (MMP1, MMP7, MMP13). Conclusion: Our findings support a two-stage therapeutic strategy in which UC-MSC secretome first alleviates inflammation, followed by UC-MSCs to promote cartilage regeneration. Post-injection rehabilitation or repeated MSC dosing may further enhance treatment efficacy, highlighting the potential of MSC-based therapies for knee OA management.
- Open Access
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1)
Effect of Adding Human Umbilical Cord Mesenchymal Stem Cells–Derived Secretome on Sperm Quality Improvement by Swim‐Up Method
Background: Suboptimal sperm quality often poses a challenge to successful fertilization. This study hypothesizes that secretome could enhance sperm quality and increase the likelihood of successful pregnancy. This research aims to assess the impact of secretome on various sperm quality parameters, including concentration, motility, and DNA fragmentation, while considering patient‐related factors such as age, duration of abstinence, and body mass index (BMI). Method: An analysis involving 45 patients enrolled in the pregnancy program at Halim Fertility Center, Stella Maris Women’s and Children’s Hospital, Indonesia, from April to September 2023 was conducted. Semen samples from these patients were subjected to the swim‐up method and divided into two groups: Group A, which underwent swim‐up without secretome, and Group B, which underwent swim‐up with the addition of secretome. DNA fragmentation analysis was performed on the sperm swim‐up results from both groups. The sperm analysis data obtained before swim‐up (pretreatment) with those of Group A and Group B were compared. Result: The demographic data revealed an average age of 37.67 ± 5.36 years, abstinence duration of 4.00 ± 1.15 days, and BMI of 28.20 ± 3.49 kg/m 2 among the patients. No significant difference was observed in sperm concentration between pretreatment, Group A, and Group B (mil/mL) (36.2 ± 18.5; 36.3 ± 18.4; 36.6 ± 19.3). However, a significant difference was found in the rapid progressive motility of sperm across pretreatment, Group A, and Group B (%) (0.48 ± 1.32; 13.7 ± 8.3; 17 ± 8.3), as well as a significant reduction in DNA fragmentation in Group B compared to Group A (%) (3.48 vs. 4.39). Conclusions: The findings suggest that secretome enhances rapid progressive motility and reduces DNA fragmentation rates without affecting sperm concentration.
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1)
Open AccessEffect of Adding Human Umbilical Cord Mesenchymal Stem Cells–Derived Secretome on Sperm Quality Improvement by Swim‐Up Method
Background: Suboptimal sperm quality often poses a challenge to successful fertilization. This study hypothesizes that secretome could enhance sperm quality and increase the likelihood of successful pregnancy. This research aims to assess the impact of secretome on various sperm quality parameters, including concentration, motility, and DNA fragmentation, while considering patient‐related factors such as age, duration of abstinence, and body mass index (BMI). Method: An analysis involving 45 patients enrolled in the pregnancy program at Halim Fertility Center, Stella Maris Women’s and Children’s Hospital, Indonesia, from April to September 2023 was conducted. Semen samples from these patients were subjected to the swim‐up method and divided into two groups: Group A, which underwent swim‐up without secretome, and Group B, which underwent swim‐up with the addition of secretome. DNA fragmentation analysis was performed on the sperm swim‐up results from both groups. The sperm analysis data obtained before swim‐up (pretreatment) with those of Group A and Group B were compared. Result: The demographic data revealed an average age of 37.67 ± 5.36 years, abstinence duration of 4.00 ± 1.15 days, and BMI of 28.20 ± 3.49 kg/m 2 among the patients. No significant difference was observed in sperm concentration between pretreatment, Group A, and Group B (mil/mL) (36.2 ± 18.5; 36.3 ± 18.4; 36.6 ± 19.3). However, a significant difference was found in the rapid progressive motility of sperm across pretreatment, Group A, and Group B (%) (0.48 ± 1.32; 13.7 ± 8.3; 17 ± 8.3), as well as a significant reduction in DNA fragmentation in Group B compared to Group A (%) (3.48 vs. 4.39). Conclusions: The findings suggest that secretome enhances rapid progressive motility and reduces DNA fragmentation rates without affecting sperm concentration.